Disease response and transplantation outcome
| . | Fludarabine/ melphalan/ alemtuzumab (n = 78) . | Fludarabine/ melphalan/MTX (n = 51) . | P . |
|---|---|---|---|
| Disease response at 3 mo after transplantation | |||
| CR | 15 (21.1%) | 19 (47.5%) | < .001 |
| PR | 0 | 8 (20%) | |
| Stable/progression free | 48 (67.6%) | 9 (22.5%) | |
| Progression | 8 (11.3%) | 4 (10%) | |
| Disease status at last follow-up3-150 | |||
| CR | 28 (47.4%) | 19 (47.5%) | .43 |
| PR | 14 (23.7%) | 8 (20%) | |
| Stable/progression free | 16 (27.1%) | 9 (22.5%) | |
| Progression | 1 (1.8%) | 4 (10%) |
| . | Fludarabine/ melphalan/ alemtuzumab (n = 78) . | Fludarabine/ melphalan/MTX (n = 51) . | P . |
|---|---|---|---|
| Disease response at 3 mo after transplantation | |||
| CR | 15 (21.1%) | 19 (47.5%) | < .001 |
| PR | 0 | 8 (20%) | |
| Stable/progression free | 48 (67.6%) | 9 (22.5%) | |
| Progression | 8 (11.3%) | 4 (10%) | |
| Disease status at last follow-up3-150 | |||
| CR | 28 (47.4%) | 19 (47.5%) | .43 |
| PR | 14 (23.7%) | 8 (20%) | |
| Stable/progression free | 16 (27.1%) | 9 (22.5%) | |
| Progression | 1 (1.8%) | 4 (10%) |
Disease status after CsA taper and DLI.